Roche to buy Ignyta for $1.7 billion
Roche has announced plans to buy US group Ignyta for $27 a share in an all-cash deal totaling around $1.7 billion, securing itself access to the latter’s experimental cancer medicines.
Read More
Tag: Ignyta
PRIME status for Ignyta’s entrectinib
European regulators have awarded Ignyta’s cancer drug entrectinib Priority Medicines (PRIME) designation, potentially placing the treatment on a faster path to approval.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
